Julie Park protects her clients’ products throughout the product lifecycle—whether it is planning for new product development, recalling an existing product, or defending clients against product liability or consumer class actions. Drawing on her deep technical and legal expertise, Julie counsels clients on consumer product safety regulation and pharmaceutical and medical device preemption while also managing complex and multijurisdictional litigation both in state and federal court.
Clients appreciate Julie’s ability to assess the practical business implications in addition to the legal impact when recommending solutions that best meet their objectives. Julie’s dedication to her clients has resulted in her selection by Super Lawyers as a “San Diego Rising Star” in 2015–2017. In 2017, Julie was recommended by Legal 500 US for Product Liability and Mass Tort Defense for Pharmaceuticals and Medical Devices companies and recognized by JD Supra as a top author in its annual Readers’ Choice Awards. The San Diego Daily Transcript recognized Julie as a “Top Young Attorney” in 2011.
Julie is committed to thought leadership and is an editor and frequent contributor to the firm’s Class Dismissed blog, which provides insights on class action and product-related issues affecting consumer-facing companies.
Julie is also committed to pro bono service and diversity in the legal profession. While at Harvard Law School, she was on the board of directors and was a student attorney at the Harvard Legal Aid Bureau, a nonprofit law firm that provides free legal services. Julie has continued her pro bono work at MoFo and has been a regular recipient of the Wiley W. Manuel Award from the California State Bar for her pro bono contributions. Julie is a member of the firm’s Diversity Strategy Committee and has also served on the Associates Steering Committee of Athena San Diego, an organization that promotes professional growth for women executives and rising managers in science and technology.
Before law school, Julie was a medicinal chemist at Pfizer researching cancer drugs.
More About Julie
Julie is a professional level violinist who can be found performing with various chamber music groups in the San Diego area. She has played with numerous orchestras, including the Harvard-Radcliffe Orchestra, the Cambridge University Chamber Orchestra, and the La Jolla Symphony.
A fertility companyRepresent a fertility company and one of its subsidiaries in mass tort and class action litigation arising out of a freezer tank failure at Pacific Fertility Center.
A major technology companyAdvise company on new products coming to market as part of a private label licensing business including diverse product lines such as personal care products, children’s furniture, automotive accessories, and educational supplies.
A fitness startup companyAdvise startup on product liability risk assessment and mitigation associated with Internet of Things and product misuse.
An air purifier companyAdvise company on regulatory and product liability risk related to its products.
A global healthcare companyRepresent European-based company in U.S. product liability litigation.
A clinical trials support companyAdvise company on product liability and regulatory risk associated with issues reported with the company’s glucose meters and coordinate advice covering regulatory requirements in the U.S., E.U. and Russia.
A healthcare companyRepresent company in a number of cases alleging failure to warn of permanent hair loss from the chemotherapy drug.
FitbitAdvised company in a class action alleging that a wearable device does not accurately track sleep as advertised and in two class actions alleging that Fitbit’s heart rate monitoring does not work as advertised. The heart rate monitoring class actions have spawned securities class actions against the company and we are coordinating the interplay between both sets of cases.
FitbitServe as national coordinating counsel for Fitbit in five class action lawsuits and over 30 personal injury lawsuits arising from the widely publicized recall of Fitbit’s Force activity tracker. We successfully conducted the recall in a short timeframe and negotiated a quick and favorable settlement of the class action litigation. We also represent Fitbit in a class action alleging that a wearable device does not accurately track sleep as advertised and in two class actions alleging that Fitbit’s heart rate monitoring does not work as advertised. The heart rate monitoring class actions have spawned securities class actions against the company and we are coordinating the interplay between both sets of cases.
Amgen Inc., et al. v. Sandoz Inc., et al.(Northern District of California). Part of a team that secured a victory on behalf of Sandoz Inc. in the first case to interpret the Affordable Care Act's Biologics Price Competition and Innovation Act (BPCIA). The federal district court ruled in Sandoz's favor on all issues before the court, adopting Sandoz's interpretation of the BPCIA in all respects. The court also denied Amgen's motions urging a contrary interpretation and seeking a preliminary injunction. The Federal Circuit and the Supreme Court later affirmed the key elements of Sandoz victory.
Global Community Monitor v. Lumber Liquidators, Inc.(Superior Court, Alameda County). Part of a team that successfully defended Lumber Liquidators, the nation’s largest specialty retailer of hardwood flooring, in a Proposition 65 trial where plaintiffs claimed that Lumber Liquidators failed to warn about cancer-causing formaldehyde in its laminate wood flooring. The matter was the catalyst for the Anderson Cooper 60 Minutes feature claiming that the Company’s products were dangerous, which led to hundreds of consumer class actions and government investigations.
Anticoagulant LitigationNational counsel for a pharmaceutical distributor in MDL proceedings in which plaintiffs allege injury from an anticoagulant.
Hamilton v. AstraZenecaRepresent a major pharmaceutical company in litigation alleging developmental disabilities arising out of in utero exposure to the company’s drug. Helped secure dismissal at trial court based on federal labeling requirements for NDA holders.
Lethal Injection MattersWorked with a major pharmaceutical company to stop the states of Missouri and Texas from using a significant anesthesia drug in their executions. Faced with the threat of litigation, both states chose alternative methods for lethal injection. Our work helped to prevent a catastrophic drug shortage, as the European Union, which publicly opposes executions and had previously banned the export of drugs used in lethal injections, threatened to impose export restrictions if this drug was used for executions anywhere in the United States.
Heparin LitigationServe as national counsel in numerous cases filed around the United States, alleging side effects from heparin-induced thrombocytopenia (HIT). Our client is the largest manufacturer of heparin, a prescription injectable anticoagulant (blood thinner) often used in hemodialysis and cardiac invasive procedures.
Consumer Product AdvisementAdvise clients on product labeling and risk mitigation on minimizing product liability through the content and format of their product labels and warnings, as well as limitations of liability presented in terms of service, for consumer electronics and consumer product manufacturers.
Neill v. Bank of AmericaWon summary judgment dismissing class action complaint alleging false advertising/deceptive business practices.
In re Hydroxycut Marketing and Sales Practices LitigationServe as national trial and coordinating counsel for a nutritional supplement manufacturer in multidistrict and state court litigation alleging that Hydroxycut, a line of nutritional supplement products, causes a variety of medical ailments, including liver damage. One hundred fifteen matters are currently pending in the Southern District of California MDL proceeding, including 22 class actions. More than 60 state court actions have been filed in Pennsylvania, New Jersey, and California.
In re Aredia and Zometa LitigationRepresented a major pharmaceutical company in MDL proceedings and state consolidated cases in which more than 200 plaintiffs claimed that pamidronate, an injectable drug used in the treatment of certain cancers, causes a degenerative condition of the jaw. On January 30, 2012, we obtained dismissals from all remaining plaintiffs in the MDL. The MDL court found that plaintiffs' claims boiled down to failure to warn claims and, therefore, were preempted under the U.S. Supreme Court's decision in Mensing. In addition to MDL proceedings in the Eastern District of New York, we represented our client in New Jersey mass tort proceedings.
©1996-2019 Morrison & Foerster LLP. All rights reserved.